A meta‐analysis comparing clinical effects of short‐ or long‐acting <scp>GLP</scp>‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Aziz, Mirna S. Abd El; Kahle, Melanie; Meier, Juris J.

doi:10.1111/dom.12804

Cited by 130 publications

(92 citation statements)

References 71 publications

(147 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,9 Glucagon like peptide-1 receptor agonists (GLP-1 RAs) have showed reduction of both fasting and postprandial glucose levels because of their multifaceted mechanism of action, primarily, glucosedependent insulin secretion and glucagon suppression, delaying of gastric emptying and appetite suppression. 11 Short-acting GLP-1 RAs are believed to be more prandialspecific because of the lack of overnight receptor interactions to control fasting glucose levels, while long-acting GLP-1 RAs have been considered more basal-specific because of tachyphylaxis of their effect on delaying gastric emptying. A recent meta-analysis comparing short-and long-acting GLP-1 RAs showed overall greater reductions in HbA1c with long-acting agents compared with short-acting agents.…”

mentioning

confidence: 99%

Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide

Umpiérrez

Pantalone

Atisso

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim: To assess the effect of dulaglutide on the relative contribution of basal hyperglycaemia (BHG) and postprandial hyperglycaemia (PPHG) to overall hyperglycaemia across HbA1c categories in patients with type 2 diabetes.Methods: Data from five phase 3 studies (N = 673) were pooled to assess the change in relative contributions of BHG and PPHG to overall hyperglycaemia across different HbA1c categories after 6 months of treatment intensification with dulaglutide 1.5 mg as monotherapy or with 1 or 2 oral medication(s) in patients with type 2 diabetes. BHG and PPHG were calculated using the area under the curve (AUC) of 7-point self-monitored plasma glucose concentration profiles. As a secondary objective, relative contribution of BHG and PPHG for dulaglutide versus liraglutide, exenatide BID and insulin glargine was assessed by individual studies at 6 months. Results: In pooled data, after 6 months of treatment intensification with dulaglutide 1.5 mg, there was a significant reduction from baseline in overall hyperglycaemia (AUC overall ) [(mean ± SE) -466.31 ± 18.32 mg*h/dL (P < 0.001)], BHG (AUC basal ) [(mean ± SE) -371.46 ± 16.36 mg*h/dL (P < 0.001)] and PPHG (AUC postprandial ) [(mean ± SE) -94.84 ± 7.97 mg*h/dL (P < 0.001)]. At baseline, relative contributions of BHG increased and PPHG decreased with increasing HbA1c levels. This pattern was maintained at 6 months, even as overall glycaemia improved with decreasing HbA1c values. Conclusions: In patients with type 2 diabetes, dulaglutide reduces HbA1c by lowering both basal and postprandial hyperglycaemia across various HbA1c levels. K E Y W O R D S basal insulin, dulaglutide, GLP-1 RAs, glycaemic control, type 2 diabetes 1 | INTRODUCTION Widely accepted treatment guidelines recommend an individualized treatment approach towards target HbA1c for patients with type 2 diabetes, based upon cardiovascular disease, life expectancy, disease duration, comorbidities, micro-and macrovascular complications, adherence and other patient-related factors. 1-4 HbA1c is a measure of overall glucose exposure during both fasting and postprandial state, and this interrelationship between the "glucose triad" of HbA1c, fasting glucose and postprandial glucose level changes with progression of the disease. 5 Monnier et al., in a study of 290 patients with type 2 diabetes managed with diet, metformin and/or sulphonylurea, showed that the relative contribution of postprandial hyperglycaemia (PPHG) decreases with increase in HbA1c and the relationship is the opposite for relative contribution of basal hyperglycaemia (BHG) to overall hyperglycaemia. 6 Moreover, the relative contribution of BHG and PPHG to overall hyperglycaemia in patients across a range of HbA1c levels of 7.3-10.2% (56.3-83.0 mmol/mol) was~50%, highlighting the need for drugs that impact both BHG and PPHG for a large proportion of patients. 6 In another study conducted by Riddle et al., in patients with mean baseline HbA1c of 8.7% (71.6 mmol/mol) treated with insulin glargine, the mean relative contribution of BHG t...

show abstract

mentioning

confidence: 99%

Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide

Umpiérrez

Pantalone

Atisso

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…В другом метаанализе АР ГПП-1 (включая лираглутид) были ассоциированы с более низкой частотой тошноты и рвоты, но с более высокой частотой диареи, чем АР ГПП-1 короткого действия [45]. Еще в одном метаанализе было показано, что снижение массы тела по сравнению с инсулинотерапией при применении АР ГПП-1 длитель-ного действия (включая лираглутид) обычно меньше, чем при применении АР ГПП-1 короткого действия [46]. Это может быть обусловлено уменьшением степени за-медления скорости опорожнения желудка при примене-нии агонистов длительного действия из-за тахифилаксии рецептора ГПП-1 с длительной активацией [12].…”

Section: сравнение ар гпп-1unclassified

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

Galstyan¹,

Karataeva²,

Yudovich³

2017

Diabetes mellitus

View full text Add to dashboard Cite

“…According to their mode of action, GLP-1RAs can be classified into short-acting preparations with once (lixisenatide) or twice (eventide) daily administration and long-acting with once daily (liraglutide) or once weekly (QW) administration (eventide QW, dulaglutide, albiglutide and semaglutide) (5). While long-acting GLP-1RAs have a stronger effect on fasting plasma glucose and overall glycemic control, short-acting preparations decrease more post-prandial blood-glucose (3,5).…”

Section: Introductionmentioning

confidence: 99%

“…While long-acting GLP-1RAs have a stronger effect on fasting plasma glucose and overall glycemic control, short-acting preparations decrease more post-prandial blood-glucose (3,5). In addition, once-weekly GLP-1RAs may improve patient compliance and quality of life compared to the short-action preparations (6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Semaglutide—the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists?

Guja

Miulescu

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Cited by 130 publications

References 71 publications

Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide

Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

Semaglutide—the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists?

Contact Info

Product

Resources

About